Antiviral antibiotic BU-3889V
    3.
    发明授权
    Antiviral antibiotic BU-3889V 失效
    抗病毒抗生素BU-3889V

    公开(公告)号:US5286649A

    公开(公告)日:1994-02-15

    申请号:US819543

    申请日:1992-01-10

    CPC分类号: C12P1/06 Y10S435/822

    摘要: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

    摘要翻译: 公开了通过新型微生物Amycolatopsis orientalis ATCC-53884的BU-3889V生产菌株的发酵生产抗病毒抗生素复合物BU-3889V及其生物活性成分A1,A2,A3,D1,D2和D3。 通过使用离子交换色谱技术分离复合物BU-3889V并将组分分离。 生物活性成分的特征在于其物理化学性质。 已经发现这些产品有效地抑制包括单纯疱疹病毒,人类免疫缺陷病毒(HIV)和流感病毒在内的病毒。

    Polysubstituted thiazolylpyridine carboxyamide antifungal antibiotic
    9.
    发明授权
    Polysubstituted thiazolylpyridine carboxyamide antifungal antibiotic 失效
    多取代噻唑吡啶羧酰胺抗真菌抗生素

    公开(公告)号:US4956374A

    公开(公告)日:1990-09-11

    申请号:US226016

    申请日:1988-07-29

    IPC分类号: C07D417/04 C12P17/16

    CPC分类号: C07D417/04 C12P17/16 C12R1/01

    摘要: Novel antifungal antibiotic compounds have the structural formula ##STR1## A preferred compound where R is 4-hydroxypentyl is denoted BU-3557B.sub.2. A complex of said compounds is produced by fermenting a culture of Sacchrothrix aerocolonigenes strain N806-4 (ATCC 53712). The complex is recovered by adsorption on nonionic porous polymer resin adsorbent and individual component compounds exhibit in vitro activity against fungi and Gram-positive bacteria and BU-3557B.sub.2 demonstrates in vitro antiprotazoal activity. BU-3557B.sub.2 demonstrates in vivo activity against C. albicans vaginal infection and BU-3557A.sub.3 (where R is 1,5-dihydroxy-5,5-dimethylpentyl) demonstrates in vivo activity against C. albicans systemic infection.

    摘要翻译: 新型抗真菌抗生素化合物具有结构式:其中R为4-羟基戊基的优选化合物为BU-3557B2。 通过发酵产气荚膜梭菌菌株N806-4(ATCC 53712)的培养物产生所述化合物的复合物。 通过非离子多孔聚合物树脂吸附剂上的吸附回收复合物,并且各组分化合物表现出对真菌和革兰氏阳性细菌的体外活性,并且BU-3557B2证明体外抗原辅素生物活性。 BU-3557B2证明体内活性针对白色念珠菌阴道感染和BU-3557A3(其中R为1,5-二羟基-5,5-二甲基戊基)表现出对白色念珠菌全身感染的体内活性。